Cover Image
市場調查報告書

創傷性腦損傷:治療·診斷開發平台(管線)和商業性展望

Traumatic Brain Injury: Therapeutic and Diagnostic Pipeline Assessment and Commercial Prospects

出版商 Arrowhead Publishers 商品編碼 138803
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
創傷性腦損傷:治療·診斷開發平台(管線)和商業性展望 Traumatic Brain Injury: Therapeutic and Diagnostic Pipeline Assessment and Commercial Prospects
出版日期: 2014年10月21日 內容資訊: 英文
簡介

創傷性腦損傷(TBI)是僅次於受創,造成幼兒及年輕成人階層的死亡及障礙的主要原因。儘管過去三十年所進行的重點式研究開發,由研究轉移到臨床依然留下莫大的課題。過去二十年間所進行的33回神經保護藥之有效性驗証第三階段實驗皆以失敗告終。結果造成沒有任何FDA認証藥的存在。但美國在2013年,為了解決 TBI的未滿足需求,而創出了NRAP(National Research Action Plan),預測將有許多定點照護診斷設備在2014年末前通過FDA的核准。

本報告提供創傷性腦損傷相關研究開發趨勢之整體分析,提供您TBI的診斷·治療現況,TBI管理的困難度,TBI的未滿足需求,治療藥及診斷設備的開發平台趨勢,彙整TBI的潛在性市場展望,主要經營者的配合措施,簡介等資料。

第1章 摘要整理

第2章 調查方法

  • 創傷性腦損傷:簡介
  • TBI缺乏明確簡潔的定義
  • TBI是具有廣泛類型的複雜性障礙
    • 原發性TBI
    • 次發性TBI
    • 局部性TBI
    • 蔓延性TBI
    • 開放性TBI
    • 封閉性TBI
  • 跌倒是TBI的主要原因
  • 特異症狀是TBI的徵兆
  • 有2階段的病理學階段
  • 沒有確立的TBI的診斷檢驗標準
  • TBI的病期分類:依腦損傷嚴重度決定
    • 輕度TBI
    • 中度TBI
    • 重度TBI
    • TBI患者大部分為輕度TBI
  • TBI的預後預測將很困難
  • 重度TBI的預後特別困難

第3章 TBI的流行病學與財政影響

  • 主要7個國家市場上的TBI流行病學
  • TBI的重大財政影響

第4章 目前TBI管理

  • TBI的管理
  • 輕度TBI的急性併發症是主要疑慮之源
  • 中度·重度TBI的管理:以避免二次受傷為目的
  • 藥理性治療:TBI併發症後形成corner stone
  • TBI的復健:並用複數的治療方法

第5章 TBI的R&D的主要課題

  • 神經保護藥的第三階段臨床試驗的失敗
  • TBI研究的願景
  • 歐巴馬政權的National Research Action Plan
  • TBI臨床試驗的課題
    • TBI患病人口的不均勻性
    • 臨床試驗設計
    • TBI的IMPACT(International Mission on Prognosis and Clinical Trials)建議
  • TBI研究的替代方法
    • TBI的系統生物學研究
    • TBI比較有效性研究
  • R&D支援的TBI生物標記的可能性
    • TBI的蛋白質體學為基礎的生物標誌物的發現
    • TBI的診斷·病患監測平台的開發
    • TBI的R&D的治療診斷(診斷/治療的融合)之可能性
  • 法律規章上的課題
  • 倫理的課題

第6章 TBI市場上的未滿足需求

  • 缺乏TBI共同的定義
  • 缺乏確立的診斷試驗
  • 輕度TBI:診斷不足
  • TBI管理未標準化
  • 沒有已批准治療藥
  • 沒有接受充分治療的高齡患者
  • 大製藥/生物科技公司TBI領域的投資不足
  • 需要國際性合作·聯盟

第7章 TBI治療藥的開發平台分析

  • 簡介
  • BHR Pharma的BHR-100KKKKK (Progesterone)
  • Teva Pharmaceuticals/Cephalon的 Nuvigil (Armodafinil)
  • Key Neurotek Pharmaceuticals的KN38-7271
  • Neuren Pharmaceuticals的NNZ-2566
  • NNZ-2566商業化的可能性
  • Neurohealing Pharmaceuticals的 NH001 (Apomorphine)
  • Neurovive Pharmaceuticals的NEUROSTAT (Ciclosporin-A)
  • Oxygen Biotherapeutics的 Oxycyte (Perflurocarbon Oxygen Carrier)
  • Vasopharm的VAS203
  • Remedy Pharmaceuticals的RP-1127

第8章 主要學術的研究·政府機關之TBI研究:概要

  • 簡介
  • 主要候補藥的藥物類別:檢討
    • 乙酰膽鹼酯酶抑制劑
    • 促血紅細胞生長素
    • 生長激素
    • 幹細胞
  • 新TBI藥的標的發現之學術研究
    • 5-Lipoxgenase Activating Proteins (FLAP) Inhibitors
    • Purinergic Receptor Antagonists
    • Proinflammatory Cytokine Inhibitors
    • Cysteine Protease Inhibitors
    • Transcranial Delivery of Glutathione Used in Innovative Dynamic Imaging Study of Mild TBI
    • Membrane Attack Complex (MAC) of the Terminal Complemental Pathway
  • 美國政府機關的新TBI藥標的發現之研究

第9章 潛在力有的TBI生物標記

  • 簡介
  • S100KKKKK B Caclcium Binding Protein
  • Neuron Specific Enolase (NSE)
  • Glial Fibrillary Acidic Protein (GFAP)
  • Neurofilament Light Protein (NFL)
  • Spectrin Breakdown Products
  • Beta-Amyloid Protein (AB)
  • Myelin Basic Protein (MBP)
  • Ubiquitin Carboxyl-Terminal Hydrolase Isoenzyme L1KKKKK (UCH-L1)
  • Tau Proteins
  • Ampar Peptide/GLUR1
  • TBI Biomarker Assay Services
    • Grace Laboratories
    • Banyan Biomarkers

第10章 TBI的POS診斷設備的開發平台分析

  • 簡介
  • Luoxis Diagnostics/Ampio Pharmaceuticals的Redoxsys Diagnostic System
  • Banyan Biomarkers的 UCH-L1/GFAP檢測化驗
  • Biodirections的Tbit Test Platform
  • SFC Fluidics的TBI診斷平台
  • Brainscope的Ahead M-100
  • Cerora的Mindreader Biosensor Biomarker Program
  • ELMindA的BNA平台
  • Neuro Assessment Systems的Neuro-Screen

第11章 潛在的TBI市場財務預測

  • 潛在的治療TBI市場:Arrowhead分析
  • TBI的潛在POC診斷設備市場相關分析
  • SWOT分析
  • 潛在的TBI市場:摘要

第12章 企業概要

  • Banayan Biomarkers Inc.
  • BHR Pharma LLC
  • Biodirection Inc.
  • Brainscope Company Inc.
  • Cerora Inc.
  • ElMindA Ltd.
  • Grace Laboratories LLC
  • KeyNeurotek Pharmaceuticals AG
  • Luoxis Diagnostics
  • Neuro Assessment Systems
  • Neurohealing Pharmaceuticals
  • Neuren Pharmaceuticals Ltd.
  • Neurovive Pharmaceuticals AB
  • Oxygen Biotherapeutics Inc.
  • Phlogistix LLC
  • Remedy Pharmaceuticals Inc.
  • SFC Fluidics LLC
  • TEVA Pharmaceutical Industries Ltd.
  • Vasopharm

第13章 文獻

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Traumatic brain injury (TBI) is the single leading cause of death and disability worldwide in children and young adults following an injury. With around 10 million new cases diagnosed and 1.5 million deaths occurring per annum globally; this ‘silent' epidemic accounts for more fatalities than diabetes or lung cancer.

Despite three decades of intensive research and development effort, translating benchside to bedside success remains the single greatest challenge in TBI. All 33 Phase III TBI clinical trials testing the efficacy of neuroprotective agents have failed over the past 20 years. Consequently, no FDA-approved TBI therapy exists.

Nevertheless, 2013 witnessed the creation of a National Research Action Plan (NRAP) to address the current unmet needs in TBI. Point-of-care (POC) diagnostic devices look set to revolutionize the diagnosis of TBI. By year end 2014, a number of POC diagnostic devices may be approved by the FDA.

Key Features:

  • Identification of the major challenges within TBI R&D including unmet needs, clinical trial design and alternative R&D approaches, the potential of biomarkers, regulatory hurdles and ethical issues
  • Clinical and commercial analysis of key Phase III TBI drug candidates and point-of-care diagnostic devices
  • An assessment of the potential financial TBI market, with seven major market forecasts to 2020 for key pipeline drug candidates and point-of-care diagnostic devices

Purchase of this report will enable you to:

  • Assess opportunities and challenges influencing strategic TBI R&D
  • Identify key TBI drug candidates and point- of-care diagnostic devices in late-phase development based on sales forecasts to 2020
  • Gain an impartial perspective of strategies that can be used to enhance commercial success

Key questions answered:

  • What are the major unmet needs in the treatment of TBI?
  • What are the leading potential TBI biomarkers?
  • Who are the key specialist players involved in the TBI market and what business models are they using to raise company performance?
  • What lessons can investors learn from failed TBI drug candidates?
  • How can companies optimize strategic TBI R&D to maximize commercial success?
  • What are the key leading drug candidates in the TBI pipeline?
  • What are the key leading point-of-care diagnostic devices in the TBI pipeline?
  • What are the anticipated revenues for key pipeline drug candidates?
  • What are the anticipated revenues for key pipeline point-of-care diagnostic devices?

Table of Contents

1. EXECUTIVE SUMMARY

  • 1.1. Scope of Traumatic Brain Injury Research and Development Highlights 2014
  • 1.2. Methodology
  • 1.3. Traumatic Brain Injury is the Leading Cause of Death and Disability Following an Injury
  • 1.4. Supportive Management Forms the Cornerstone of TBI Treatment
  • 1.5. Failure of Over 30 Phase III Trials Presents Major Research and Development (R&D) Challenges in TBI
  • 1.6. There are Numerous Unmet Needs in TBI
  • 1.7. The Late-Stage Therapeutic TBI Pipeline is Limited
  • 1.8. Emerging TBI Diagnostic Products
  • 1.9. Financial Analysis of the Potential TBI Market

2. TRAUMATIC BRAIN INJURY: DISEASE BACKGROUND

  • 2.1. An Introduction to Traumatic Brain Injury
  • 2.2. There is No Clear, Concise Definition of TBI
  • 2.3. TBI is a Complex Disorder with a Range of Typologies
    • 2.3.1. Primary TBI
    • 2.3.2. Secondary TBI
    • 2.3.3. Focal TBI
    • 2.3.4. Diffuse TBI
    • 2.3.5. Open TBI
    • 2.3.6. Closed TBI
  • 2.4. Falls are the Leading Cause of TBI
  • 2.5. Specific Symptoms are Indicative of TBI
  • 2.6. Two Pathological Stages are Involved in TBI
  • 2.7. There is No Gold-Standard TBI Diagnostic Test
    • 2.7.1. Glasgow Coma Score
    • 2.7.2. Rancho Los Amigos Scale
    • 2.7.3. Westmead Post Traumatic Amnesia (PTA) Scale
  • 2.8. The Staging of TBI is Dependent Upon Brain Injury Severity
    • 2.8.1. Mild TBI
    • 2.8.2. Moderate TBI
    • 2.8.3. Severe TBI
    • 2.8.4. The Majority of the TBI Patient Population Sustain Mild Brain Injuries
  • 2.9. Predicting the Prognosis of TBI is Difficult
    • 2.9.1. Glasgow Outcome Scale
    • 2.9.2. Disability Rating Scale
    • 2.9.3. The NIH's International Mission for Prognosis and Clinical Trial (IMPACT) Prognosis Model
    • 2.9.4. The MRC's Corticosteroid Randomization After Significant Head Injury (CRASH) Prognosis Model
  • 2.10. The Prognosis of Severe TBI is Particularly Poor
    • 2.10.1. Numerous Complications are Associated with TBI

3. THE EPIDEMIOLOGY AND FINANCIAL IMPLICATIONS OF TBI

  • 3.1. Epidemiology of TBI in the Seven Major Markets
    • 3.1.1. Road Traffic Accidents Set To Become the Third Leading Cause of Global Disease and Disability
    • 3.1.2. The incidence of Combat-Related TBI is Rising
  • 3.2. The Financial Impact of TBI is High

4. THE CURRENT MANAGEMENT OF TBI

  • 4.1. The Management of TBI
  • 4.2. Acute Complications of Mild TBI are a Priority Concern
  • 4.3. The Management of Moderate and Severe TBI Attempts to Minimize Secondary Injury
  • 4.4. Pharmacological Treatment Forms the Cornerstone of Post TBI Complications
  • 4.5. TBI Rehabilitation Involves a Multi Therapy Approach

5. THE MAJOR CHALLENGES OF TBI RESEARCH AND DEVELOPMENT (R&D)

  • 5.1. Failure of Over 30 TBI Phase III Clinical Trials of Neuroprotectives in the Past 20 Years
  • 5.2. The Vision of TBI Research
  • 5.3. Obama's National Research Action Plan
  • 5.4. TBI Clinical Trial Challenges
    • 5.4.1. Heterogeneity of the TBI Population
    • 5.4.2. Clinical Trial Design
    • 5.4.3. International Mission on Prognosis and Clinical Trials in TBI (IMPACT) Recommendations
  • 5.5. Alternative Approaches to TBI Research
    • 5.5.1. Systems Biology Research in TBI
    • 5.5.2. Comparative Effectiveness Research in TBI
  • 5.6. The Potential of TBI Biomarkers to Aid R&D
    • 5.6.1. Proteomics-Based Biomarker Discovery in TBI
    • 5.6.2. TBI Diagnostic and Patient Monitoring Platform Development
    • 5.6.3. The Potential of Theranostics in TBI R&D
  • 5.7. TBI Regulatory Issues
  • 5.8. TBI Ethical Challenges

6. UNMET NEEDS IN THE TBI MARKET

  • 6.1. Lack of a Universally Accepted Definition of TBI
  • 6.2. Lack of a Gold-Standard TBI Diagnostic Test
  • 6.3. Under Diagnosis of Mild TBI
  • 6.4. Management of TBI is Not Standardized
  • 6.5. No Approved TBI Treatment is Available
  • 6.6. Elderly TBI Patients are Underserved
  • 6.7. Lack of Big Pharma/Biotech Investment in the TBI Arena
  • 6.8. International TBI Collaborations and Alliances are Required

7. TBI THERAPEUTIC PIPELINE ANALYSIS

  • 7.1. Introduction to the TBI Therapeutics Pipeline
  • 7.2. BHR Pharma'S BHR-100 (Progesterone)
    • 7.2.1. BHR-100's SyNAPSe Trial
  • 7.3. Teva Pharmaceuticals/Cephalon's Nuvigil (Armodafinil)
    • 7.3.1. Nuvigil's Phase II Trial Results
  • 7.4. Key Neurotek Pharmaceuticals' KN38-7271
  • 7.5. Neuren Pharmaceuticals' NNZ-2566
    • 7.5.1. NNZ-2566's Intrepid- 2566 Trial
    • 7.5.2. NNZ-2566 Oral Formulation Trials
  • 7.6. NNZ-2566'S Commercialization Potential
  • 7.7. Neurohealing Pharmaceuticals' NH001 (Apomorphine)
  • 7.8. Neurovive Pharmaceuticals' NEUROSTAT (Ciclosporin-A)
    • 7.8.1. NeuroSTAT's Clinical Trials
    • 7.8.2. NeuroSTAT's Commercialization Potential
  • 7.9. Oxygen Biotherapeutics' Oxycyte (Perflurocarbon Oxygen Carrier)
  • 7.10. Vasopharm's VAS203
    • 7.10.1. VAS203's Nostra Trial Results
  • 7.11. Remedy Pharmaceuticals' RP-1127
    • 7.11.1. RP-1127 Clinical Trials
    • 7.11.2. RP-1127 Commercialization Potential

8. OVERVIEW OF KEY ACADEMIC AND GOVERNMENTAL TBI RESEARCH

  • 8.1. Introduction to Academia and Governmental TBI Research
  • 8.2. Review of Leading TBI Pipeline Drug Classes
    • 8.2.1. Acetylcholinesterase Inhibitors
    • 8.2.2. Erythropoietin
    • 8.2.3. Growth Hormone
    • 8.2.4. Stem Cells
  • 8.3. Academic Research for the Discovery of New TBI Drug Targets
    • 8.3.1. 5-Lipoxgenase Activating Proteins (FLAP) Inhibitors
    • 8.3.2. Purinergic Receptor Antagonists
    • 8.3.3. Proinflammatory Cytokine Inhibitors
    • 8.3.4. Cysteine Protease Inhibitors
    • 8.3.5. Transcranial Delivery of Glutathione Used in Innovative Dynamic Imaging Study of Mild TBI
    • 8.3.6. Membrane Attack Complex (MAC) of the Terminal Complemental Pathway
  • 8.4. US Governmental Agency Research for the Discovery of New TBI Drug Targets
    • 8.4.1. US Department of Veterans Affairs
    • 8.4.2. US Department of Defense
    • 8.4.3. National Institute of Neurological Disorders and Stroke

9. POTENTIAL TBI BIOMARKERS

  • 9.1. Introduction to Potential TBI Biomarkers
  • 9.2. S100 B Caclcium Binding Protein
  • 9.3. Neuron Specific Enolase (NSE)
  • 9.4. Glial Fibrillary Acidic Protein (GFAP)
  • 9.5. Neurofilament Light Protein (NFL)
  • 9.6. Spectrin Breakdown Products
  • 9.7. Beta-Amyloid Protein (AB)
  • 9.8. Myelin Basic Protein (MBP)
  • 9.9. Ubiquitin Carboxyl-Terminal Hydrolase Isoenzyme L1 (UCH-L1)
  • 9.10. Tau Proteins
  • 9.11. Ampar Peptide/GLUR1
  • 9.12. TBI Biomarker Assay Services
    • 9.12.1. Grace Laboratories
    • 9.12.2. Banyan Biomarkers

10. TBI POINT OF CARE DIAGNOSTIC DEVICES PIPELINE ANALYSIS

  • 10.1. Introduction to the TBI Point of Care Diagnositc Devices Pipeline
  • 10.2. Luoxis Diagnostics/Ampio Pharmaceuticals' Redoxsys Diagnostic System
    • 10.2.1. RedoxSYS Diagnostic System's Phase III Isolated TBI Trial Results
    • 10.2.2. RedoxSYS Diagnostic System's Commercialization Potential
  • 10.3. Banyan Biomarkers' UCH-L1/GFAP Detection Assay
    • 10.3.1. UCH-L1/GFAP Detection Assay Commercialization Potential
  • 10.4. Biodirections' Tbit Test Platform
    • 10.4.1. Tbit Test Platform's Commercialization Potential
  • 10.5. SFC Fluidics' TBI Diagnostic Platforms
    • 10.5.1. SFC Fluidics' TBI Diagnostic Platforms Commercialization Potential
  • 10.6. Brainscope's Ahead M-100
    • 10.6.1. Ahead M-100's Clinical Trial Results
    • 10.6.2. Ahead M-100 Commercialization Potential
  • 10.7. Cerora's Mindreader Biosensor Biomarker Program
    • 10.7.1. Mindreader's Commercialization Potential
  • 10.8. ELMindA's BNA Platform
    • 10.8.1. BNA Platform's Commercialization Potential
  • 10.9. Neuro Assessment Systems' Neuro-Screen
    • 10.9.1. Neuro-Screen's Commercialization Potential

11. FINANCIAL FORECAST OF THE POTENTIAL TBI MARKET

  • 11.1. Arrowhead's Analysis of the Potential Therapeutic TBI Market
  • 11.2. Analysis of the Potential TBI POC Diagnostic Devices Market
  • 11.3. SWOT Analysis of the Potential TBI Market
  • 11.4. Summary of the Potential TBI Market

12. COMPANY BRIEFS

  • 12.1. Banayan Biomarkers Inc.
  • 12.2. BHR Pharma LLC
  • 12.3. Biodirection Inc.
  • 12.4. Brainscope Company Inc.
  • 12.5. Cerora Inc.
  • 12.6. ElMindA Ltd.
  • 12.7. Grace Laboratories LLC
  • 12.8. KeyNeurotek Pharmaceuticals AG
  • 12.9. Luoxis Diagnostics
  • 12.10. Neuro Assessment Systems
  • 12.11. Neurohealing Pharmaceuticals
  • 12.12. Neuren Pharmaceuticals Ltd.
  • 12.13. Neurovive Pharmaceuticals AB
  • 12.14. Oxygen Biotherapeutics Inc.
  • 12.15. Phlogistix LLC
  • 12.16. Remedy Pharmaceuticals Inc.
  • 12.17. SFC Fluidics LLC
  • 12.18. TEVA Pharmaceutical Industries Ltd.
  • 12.19. Vasopharm

13. BIBLIOGRAPHY

List of Tables

  • Table 1: TBI Incidence Forecast in 2014 and 2020 in the Seven Major Markets
  • Table 2: TBI Pipeline Candidates Undergoing Late-Stage Clinical Development by Pharma/Biotech Companies
  • Table 3: Late-stage TBI POC Diagnostic Devices Pipeline, Jan 2014
  • Table 4: Financial Forecast of the Potential TBI Market, in 2014 and 2020 in the US and EU ($ billions)
  • Table 5: The Glasgow Coma Score
  • Table 6: The Ranchos Los Amigos Scale
  • Table 7: Summary of TBI Severity Stratification
  • Table 8: The Glasgow Outcome Scale
  • Table 9: The Disability Rating Scale
  • Table 10: The Disability Rating Scale Prognosis Outcome
  • Table 11: Complications Associated with TBI
  • Table 12: Crude Incidence Rate of TBI (per 100,000) in the Seven Major Markets, 2014
  • Table 13: TBI Incidence Forecast in the Seven Major Markets, 2014-2020
  • Table 14: Mild TBI Incidence Forecast in the Seven Major Markets, 2014-2020
  • Table 15: Moderate TBI Incidence Forecast in the Seven Major Markets, 2014-2020
  • Table 16: Severe TBI Incidence Forecast in the Seven Major Markets, 2014-2020
  • Table 17: Brain Trauma Foundation Guidelines for the Acute Management of Severe TBI
  • Table 18: Management of Common Post-TBI Complications
  • Table 19: Failed Phase III Clinical Trials of Novel Neuroprotectives in Moderate and Severe TBI over the Past 30 Years
  • Table 20: National Research Action Plan Deadline Targets in TBI
  • Table 21: IMPACT Recommendations for the Use of Common Outcome Measures in TBI
  • Table 22: Applications of TBI Diagnostic and Patient Monitoring Platforms
  • Table 23: Incentives Granted to Orphan Drug Developers
  • Table 24: TBI Therapeutic Pipeline, Jan 2014
  • Table 25: Comparison of ProTECT II and Xiao Clinical Trials
  • Table 26: Comparison of SyNAPSe and ProTECT III Clinical Trials
  • Table 27: TBI Point- of-Care Diagnostic Devices Pipeline, Jan 2014
  • Table 28: Arrowhead's Financial Forecast of the Potential Therapeutic TBI Market in the US and EU, 2014-2020 ($ millions)
  • Table 29: Arrowhead's Financial Forecast of the Potential TBI POC Diagnostic Devices Market in the US and EU, 2014-2020 ($ millions)
  • Table 30: Arrowhead's Financial Forecast of the Potential TBI Market in the US and EU, 2014-2020 ($ billions)

List of Figures

  • Figure 1: TBI Incidence Forecast in 2014 and 2020 in the Seven Major Markets
  • Figure 2: Major Unmet Needs in TBI
  • Figure 3: Finanical Forecast of the Potential TBI Market, in 2014 and 2020 in the US and EU ($ billions)
  • Figure 4: The Anatomy of the Human Brain
  • Figure 5: Cause of all TBIs within the US General Population, 2010
  • Figure 6: The Pathophysiological Pathways Involved in Secondary Brain Injury
  • Figure 7: TBI Patient Population by Brain Injury Severity
  • Figure 8: TBI Incidence Forecast in the Seven Major Markets, 2014-2020
  • Figure 9: Mild TBI Incidence Forecast in the Seven Major Markets, 2014-2020
  • Figure 10: Moderate TBI Incidence Forecast in the Seven Major Markets, 2014-2020
  • Figure 11: Severe TBI Incidence Forecast in the Seven Major Markets, 2014-2020
  • Figure 12: Info graphic on Global Road Traffic Accidents
  • Figure 13: Number of Persons Injured in a Road Traffic Accident within the US, 2000-2011
  • Figure 14: Total Worldwide Number of TBIs Diagnosed in US Military Personnel, 2000-2012
  • Figure 15: The Total Worldwide Number of Combat-Related TBIs Diagnosed in US Military Personnel, 2000-2012
  • Figure 16: Management Algorithm of TBI According to Glasgow Coma Score
  • Figure 17: NRAP's Approach to Address the Current Unmet Needs in TBI R&D
  • Figure 18: The Use of Biomarkers to Maximize TBI R&D
  • Figure 19: Systems Biology-Based Selection of Potential TBI Biomarkers,
  • Figure 20: Number of Phase III Randomized Controlled Trials in Moderate and Severe TBI per Five -Year Time Period Between1980 to 2005
  • Figure 21: Potential TBI Biomarkers
  • Figure 22: Illustrative of BNA Platform's Brain Network Activation Patterns
  • Figure 23: Arrowhead's Financial Forecast of the Potential Therapeutic TBI Market in the US and EU, 2014-2020 ($ millions)
  • Figure 24: Arrowhead's Financial Forecast of the Potential TBI Therapeutics Market in the US and EU, 2014-2020 ($ millions)
  • Figure 25: SWOT Analysis of the TBI Market, 2014
  • Figure 26: Arrowhead's Financial Forecast of the Potential TBI Market in the US and EU, 2014-2020 ($ billions)
Back to Top